Clinical Trial Update: A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery [Phase 2]

View source ↗

Summary

A Phase 2 randomized, open-label pharmacokinetics study comparing a 2 g azithromycin sustained-release dose with a 500 mg azithromycin tablet in cancer patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Azithromycin Sustained-Release (2 g) (azithromycin)
• Azithromycin Tablet (500 mg) (azithromycin)

Snippet

Sponsor: Pfizer | Conditions: Pharmacokinetics | Phase 2 | Status: COMPLETED